Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
Summary
S06422 would expand an existing New York prescription-label privacy provision. Under current law referenced in the bill, certain prescriptions for mifepristone and misoprostol may list the dispensing health care practice rather than the individual dispenser. This bill extends that option to additional medications and drug classes, including gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, and hormone replacement therapy drugs used for gender dysphoria. It also allows the prescribing health care practice’s name to appear instead of the individual prescriber’s name on the label, at the prescriber’s request in some cases.
The bill further adds a new patient-notification requirement. A prescriber must inform the patient when the prescription label will include the name or address of the prescribing health care practice instead of the prescriber’s name. The measure takes effect immediately and amends both the Education Law and the Public Health Law.
Impact
The bill would amend sections of the Education Law governing prescription labeling and add a new section to the Public Health Law requiring patient notice. Its practical effect is to broaden confidentiality and privacy options for prescriptions tied to reproductive health care and gender-affirming care, while preserving a disclosure obligation to the patient. Pharmacies, prescribers, and dispensing practices would need to adjust labeling and notification procedures for the covered medications and drug classes.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of support or opposition in the available materials. Based on the bill’s structure, it appears designed as a privacy-protection measure for patients and providers, especially in sensitive care contexts. The absence of recorded debate means the overall sentiment cannot be measured from the supplied history.
Contention
The main point of potential contention is the scope of the privacy protection: the bill extends label-name substitution beyond abortion medications to gender-affirming hormone-related drugs and other listed therapies, which may draw differing views depending on attitudes toward reproductive health and gender-affirming care. Another possible issue is the balance between patient privacy and transparency, since the bill permits practice-level labeling but requires prescribers to notify patients of that change. No specific objections or supporters are identified in the provided record.
Same As
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.
AN ACT Relating to increasing access to prescription hormone therapy to patients of all ages by requiring health plans to provide reimbursement for a 12-month refill of prescription hormone therapy obtained at one time by an enrollee;
Hospitals and Related Institutions; hormone therapies and puberty-blocking medications for certain purposes to minors; prohibit prescribing or administering
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.
Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.